The Cards and Payments Industry in Austria Emerging Trends and Opportunities to 2020 Now Available at iData Insights
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>The</strong> <strong>Cards</strong> <strong>and</strong> <strong>Payments</strong> <strong>Industry</strong> <strong>in</strong> <strong>Austria</strong>:<br />
Emerg<strong>in</strong>g <strong>Trends</strong> <strong>and</strong> <strong>Opportunities</strong> <strong>to</strong> <strong>2020</strong> <strong>Now</strong><br />
<strong>Available</strong> <strong>at</strong> iD<strong>at</strong>a <strong>Insights</strong><br />
SUMMARY Delve<strong>Insights</strong> Report, Yers<strong>in</strong>ia Pestis Infections-Global API Manufacturers, Marketed <strong>and</strong><br />
Phase III Drugs L<strong>and</strong>scape, 2016 , provides comprehensive <strong>in</strong>sights about the marketed drugs, drug<br />
sales, Phase III pipel<strong>in</strong>e drugs <strong>and</strong> their API Manufacturersacross the globe. A key objective of the<br />
Yers<strong>in</strong>ia Pestis Infections Report is <strong>to</strong> underst<strong>and</strong> the market <strong>and</strong> pipel<strong>in</strong>e st<strong>at</strong>us of the drugs around the<br />
Yers<strong>in</strong>ia Pestis Infections <strong>to</strong> explore the generic development opportunities, licens<strong>in</strong>g opportunities <strong>and</strong><br />
<strong>to</strong> ga<strong>in</strong> competitive advantage on design<strong>in</strong>g pipel<strong>in</strong>e startegies. <strong>The</strong> DelveInsight s Report provides the<br />
his<strong>to</strong>rical <strong>and</strong> forecasted sales of the drugs till 2018. <strong>The</strong> Report gives <strong>in</strong>sights <strong>in</strong><strong>to</strong> p<strong>at</strong>ents provid<strong>in</strong>g the<br />
p<strong>at</strong>ent protection d<strong>at</strong>a <strong>and</strong> market<strong>in</strong>g exclusivity of all the drugs across the Yers<strong>in</strong>ia Pestis Infections.<br />
While the lead<strong>in</strong>g br<strong>and</strong>s, companies <strong>and</strong> chemicals are considered thoroughly, DelveInsight s report<br />
also provides details on the Global API Manufacturers across the globe cover<strong>in</strong>g Drug Master Fil<strong>in</strong>gs of<br />
US, Europe <strong>and</strong> API Manufacturers <strong>in</strong> Asia specifically Ch<strong>in</strong>a <strong>and</strong> India. Please note:This report requires<br />
certa<strong>in</strong> upd<strong>at</strong>es. We have all the <strong>in</strong>form<strong>at</strong>ion available but require 3 bus<strong>in</strong>ess days <strong>to</strong> complete the<br />
process <strong>and</strong> ensure it is as up-<strong>to</strong>-d<strong>at</strong>e as possible. Certa<strong>in</strong> sections <strong>in</strong> the report may be removed or<br />
altered based on the availability <strong>and</strong> relevance of d<strong>at</strong>a for the <strong>in</strong>dic<strong>at</strong>ed disease.<br />
Read more<br />
Table of Conetents<br />
1. Indic<strong>at</strong>ion Overview<br />
2. Market Drugs L<strong>and</strong>scape<br />
2.1 Marketed Drugs<br />
2.2 Marketed Details of Drugs by Applic<strong>at</strong>ion Type<br />
2.3 Marketed Details of Drugs (NDA) by Market<strong>in</strong>g St<strong>at</strong>us<br />
2.4 Marketed Details of Drugs by P<strong>at</strong>ent Expir<strong>at</strong>ion Timel<strong>in</strong>e<br />
3. Global API Manufacturers Assessment<br />
3.1 API Manufacturers by United St<strong>at</strong>es Drug Master File (US DMF) St<strong>at</strong>us<br />
3.2 API Manufacturers by US DMF St<strong>at</strong>us (Drug Specific)<br />
3.3 API Manufacturers <strong>in</strong> Europe by Country<br />
3.4 API Manufacturers <strong>in</strong> India by St<strong>at</strong>e<br />
3.5 API Manufacturers <strong>in</strong> Ch<strong>in</strong>a by Prov<strong>in</strong>ce<br />
3.6 Marketed Details of Approved Drugs by Geography<br />
4. Phase III Drugs L<strong>and</strong>scape<br />
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipel<strong>in</strong>e Drugs<br />
4.2 API Manufacturers by US DMF St<strong>at</strong>us (Drug Specific)<br />
5. Drugs Market D<strong>at</strong>a <strong>and</strong> Forecasted Sales Figure-2018
6. Marketed Drugs for Yers<strong>in</strong>ia Pestis Infections<br />
6.1 Drug Name<br />
6.1.1 Drug Description<br />
6.1.2 Global Active Pharmaceutical Manufacturers for Drug<br />
6.1.3 Approval St<strong>at</strong>us of Drug<br />
6.1.4 P<strong>at</strong>ent <strong>and</strong> Exclusivity Details for Drug<br />
6.1.5 Company Profile <strong>and</strong> F<strong>in</strong>ancials<br />
7. Phase III Drugs for Yers<strong>in</strong>ia Pestis Infections<br />
7.1 Drug Name<br />
7.1.1 Drug Description<br />
7.1.2 United St<strong>at</strong>es Drug Master File (DMF)<br />
8. Discont<strong>in</strong>ued Drugs for Yers<strong>in</strong>ia Pestis Infections<br />
9. Appendix<br />
10. Methodology<br />
11. Consult<strong>in</strong>g Services<br />
12. Contact Us<br />
13. Disclaimer<br />
Read more
Change language